Neve Yarak, Israel — February 12, 2026 — Leads & Copy —
N2OFF, Inc. (NASDAQ: NITO) recently announced positive preliminary in vitro data from its wholly-owned subsidiary, MitoCareX Bio Ltd., demonstrating the inhibition of pro-inflammatory responses in human immune cells. MitoCareX Bio is a specialty biotechnology company focused on developing small‑molecule drugs targeting human mitochondrial carriers.
The in vitro data indicates that select candidates from MitoCareX Bio’s focused library of small‑molecule candidates, assembled using MITOLINE™‑derived models, reduce key inflammatory markers in human immune cells. These candidates are being evaluated in proprietary in-vitro assays that capture mitochondrial function, inflammatory signalling, and metabolic readouts. The data provides an initial line of evidence that mitochondrial carrier modulation can deliver anti‑inflammatory benefits. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications, including diseases related to metabolic syndrome.
The company’s MITOLINE™ algorithm is designed to overcome a bottleneck in mitochondrial drug discovery, the lack of solved 3D structures for most human mitochondrial carriers. MITOLINE™ uses advanced sequence-based analyses to create 3D comparative models of mitochondrial carrier proteins, enabling MitoCareX to characterize substrate translocation binding sites for its virtual screening campaigns. The platform supports rapid identification of novel small‑molecule scaffolds that engage mitochondrial carriers implicated in oncology, autoimmune, and metabolic‑inflammatory diseases.
Inflammatory and inflammatory metabolic diseases represent one of the fastest‑growing therapeutic areas in global pharma. Anti‑inflammatory drugs are projected to grow from approximately $122 billion in 2024 to nearly $275 billion by 2034, a CAGR of approximately 8.4%. Small‑molecule immunomodulators alone are projected to expand from around $188 billion in 2025 to more than $350 billion by 2035, a CAGR of approximately 6.5%. Metabolic disorder therapeutics, which include key inflammatory metabolic diseases such as diabetes and related syndromes, are estimated at around $77 billion in 2024 and forecast to surpass $120 billion by 2030.
MitoCareX Bio plans to advance its most promising mitochondrial‑targeted anti‑inflammatory candidates toward pre-clinical studies, while continuing to broaden the MITOLINE™‑powered discovery engine across additional mitochondrial carrier targets.
N2OFF owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer therapeutics and other diseases through the mitochondrial SLC25 protein family. N2OFF also invests in European renewable energy assets utilizing an RTB (Ready to Build) business model and is the lead investor in four solar projects across three European Union countries, introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.
Source: N2OFF, Inc.
